ITEL was founded in Italy, initially operating in telecommunications and radio-relay technologies.

ITEL manufactured its first shielding system for a superconductive MRI installation in Modena, Italy.

Development of mobile MRI and mammography units.

Expansion into electromagnetic compatibility testing.

Development of ITEL's magnetic interference compensation technology.

Development of the OSB shielding solution for Open MRI environments.

Participation at the RSNA Meeting in Chicago.

ITEL began construction of a new radiopharmaceutical division, expanding its activities into nuclear medicine and radiopharmaceutical production.

ITEL established Itelpharma, its radiopharmaceutical division dedicated to the production of radiopharmaceuticals for PET diagnostics and services for nuclear medicine, radiation protection and microbiology.

ITEL launched the first research and development phase of a linear proton accelerator project in cooperation with INFN and ENEA.

ITEL expanded its activities into the design and implementation of complex healthcare facilities and complete diagnostic imaging departments.

ITEL advanced research into Helium-3 hyperpolarization systems for magnetic resonance imaging applications.

ITEL received a special recognition connected to the “Andrea Pininfarina” award for innovative companies.

Michele Diaferia was appointed CEO, while ITEL also received a two-star legality rating from the Italian Antitrust Authority.

ITEL signed an agreement with Advanced Accelerator Applications S.A. for the production and distribution of F-18 radiopharmaceuticals to nuclear medicine facilities in Southern Italy.

ITEL established a second production line at the Itelpharma facility through an investment of approximately €2 million.

Linearbeam was established as an ITEL spin-off focused on developing a complete proton therapy system based on a linear proton accelerator, supported by an investment of approximately €14.9 million.

ITEL and ENEA formalized a cooperation agreement supporting the ERHA project, an innovative linear proton accelerator system for oncological radiotherapy.

Italian Prime Minister Giuseppe Conte visited ITEL and Linearbeam’s facilities following the growing interest generated by the ERHA proton therapy project.

ITEL secured access to €3.2 million in Minibond financing to support the group’s growth plans and increase production capacity, particularly within its radiopharmaceutical activities.

The ITEL Group was included among the “100 Italian Life Sciences Stories,” recognizing its contribution to healthcare technology, scientific research and the Italian life sciences sector.

ITEL celebrated 40 years of activity, marking four decades of development in diagnostic imaging, biomedical technologies, radiopharmaceuticals and healthcare innovation.

ITEL’s corporate profile reports more than 40 years of experience, over 4,000 MRI system installations and a presence in more than 40 countries, reflecting the group’s continued international development in healthcare technologies.